Fundraising Fox
/Companies
Sign in

zPREDICTA

acquired by Predictive OncologyYC S15

San Francisco, US · Founded 2014 · 2 employees · 2 known investors

Find your way into zPREDICTA

Sign up to see every warm intro you have to zPREDICTA

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the zPREDICTA team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

zPREDICTA manufactures three-dimensional tissue culture models derived from patient samples that recreate human organ microenvironments for drug testing. Pharmaceutical companies and researchers use the models to evaluate cancer drug candidates and predict clinical efficacy before human trials.

Also known as zPREDICTA, Inc. (fka Ixchel Scientific) · Ixchel Scientific

BiotechHealthtechUnited States of AmericaAmerica / Canada

Founders & leadership· Y Combinator alumni (S15)

zPREDICTA was founded in 2014 by Mukti Parikh.

MPMukti Parikh
Mukti ParikhCo-founder, Chief Scientific Officer (YC S15, Acquired by Predictive Oncology)2015–2019Mukti Parikh developed machine learning models for pharmaceutical R&D at OneThree Biotech and previously co-founded zPREDICTA, where he created patented 3D cell culture platforms for oncology drug testing before the company's acquisition by Predictive Oncology. He holds expertise in data science, cancer biology, and scaling AI/ML applications in life sciences.
JK
Julia KirshnerCEOformer

Investors · 2

Great Oaks Venture CapitalreportedNew York · $50K – $500K

How we know: Y Combinator's founder network · Not right? Tell us

The YC application· Summer 2015 batch

What they told YC

How long have each of you been working on this? How much of that has been full-time? Please explain.
The founders spent the last four years developing, testing, and validating their PD-3D model in cell culture and two animal models. The work involved no software development.
What is your company going to make? Please describe your product and what it does or will do.
The company's Patient-Derived 3D Tissue Culture (PD-3D) platform is a ready-to-use, organ-specific system that reproduces the human tissue environment to test drug candidates and drug combinations before human trials. It targets biotechnology and pharmaceutical customers, and the founders state that incorporating it into preclinical testing can cut drug development timelines and costs by 15-35%.

Summarized from the founders' answers on their Y Combinator profile.

Related companies · 3

IsablIsabl develops whole genome and transcriptome sequencing technology for cancer diagnosis, delivering comprehensive genomic profiling and treatment options to physicians and research teams. The company provides rapid cancer diagnostic tests in clinically relevant timeframes to improve outcomes for cancer patients globally.
Yemaachi BiotechnologyYemaachi creates a diverse cancer bio-database to develop oncology drugs effective across diverse patient populations. The company develops precision oncology research, diagnostics, and therapeutics with a focus on inclusion for global communities.
ResistanceBioResistanceBio develops treatments to address drug resistance in cancer patients.

Companies working in the same space as zPREDICTA.

Legal entities · 2

corporate structure
zPREDICTA, Inc.
zPREDICTA, Inc. (fka Ixchel Scientific)

Frequently asked questions

What does zPREDICTA do?
zPREDICTA manufactures three-dimensional tissue culture models derived from patient samples that recreate human organ microenvironments for drug testing. Pharmaceutical companies and researchers use the models to evaluate cancer drug candidates and predict clinical efficacy before human trials.
Who founded zPREDICTA?
zPREDICTA was founded by Mukti Parikh in 2014.
Who are zPREDICTA's investors?
zPREDICTA's investors include Y Combinator, Great Oaks Venture Capital.
Who acquired zPREDICTA?
zPREDICTA was acquired by Predictive Oncology.
Where is zPREDICTA headquartered?
zPREDICTA is headquartered in San Francisco, US.